Osteogenesis via autologous cellular contribution

This phrase describes the process in which bone is regenerated through the action of a patient's own cells. Autologous bone grafts and autologous cell-based therapies use populations of osteoprogenitor cells, mesenchymal stem cells, and other bone marrow-derived cells to directly contribute to new bone formation. These cells, often characterized by markers such as Runx2, ALP, and osteocalcin, proliferate and differentiate into osteoblasts that synthesize new bone tissue. The process is regulated by key signaling pathways (BMP, Wnt/β-catenin, Notch). Osteogenesis via autologous cells is the basis for many bone repair therapies but is best understood as a biological phenomenon, not as a druggable molecular target[1][2][3][5][7].\n\nIf you are looking for a specific molecule, receptor, or target involved in this process, candidates include:\n- Bone morphogenetic protein receptors (BMP receptors)\n- Wnt signaling pathway receptors\n- Mesenchymal stem cell surface markers (e.g., CD71, CD73, CD90, CD105)[3][5]\n\nHowever, "Osteogenesis via autologous cellular contribution" itself should not be annotated as a canonical molecular target.

Other names

autologous cell contribution to bone regenerationautologous cell-driven osteogenesis

Activation of signaling pathways promoting osteogenic differentiation (BMP, Wnt/β-catenin, Notch)\nParacrine and autocrine stimulation by transplanted cells or applied growth factors